Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the third quarter of fiscal year 2022, which include consolidated financial results for GRAIL.

For its first full quarter following a business combination, QuidelOrtho after the close of the market on Wednesday reported third-quarter revenues of $783.8 million, an increase of 54% compared to $509.8 million in Q3 2021 and in line with preliminary estimates announced in October.

Snibe announced its 2022 Q3 report, the company achieved operating revenue of RMB 880 million, up 31.67% year-on-year; net profit attributable to shareholders of the listed company was RMB 355 million, up 49.72% year-on-year.

Bruker reported before the open of markets on Thursday that revenues in the third quarter rose 5 percent year over year.

Twist Bioscience said on Tuesday that it has inked a partnership with Illumina to produce the co-branded Twist Bioscience for Illumina Exome 2.0 Plus panel for disease research.

In the evening of October 24, Beijing Hotgen Biotech Co., Ltd. (stock code: 688068) released its third quarter report for 2022. In the third quarter, Hotgen 's revenue and net profit continued to jump, achieving CNY 963 million revenue with a year-on-year increase of 391.95%

Veracyte reported after close of market Wednesday that its third quarter revenues increased 25 percent year over year, beating Wall Street estimates and prompting the firm to increase its full-year revenue guidance.

Castle Biosciences reported after the close of the market on Wednesday that its third quarter revenues rose 58 percent year over year, driven by record diagnostic test volume for the firm.

On October 27, Mindray (300760) released its third quarterly report. The report showed that in the first three quarters of 2022, Mindray achieved revenue of CNY 23.3 billion, an increase of 20.1% year-on-year, and recorded net profit of CNY 8.1 billion, an increase of 21.6% year-on-year.

Hologic reported after the close of the market on Monday that a continued decline in sales of COVID-19 assays and ongoing difficulties securing semiconductor chips contributed to an overall 28 percent year-over-year decline in its fiscal fourth quarter revenues.

Myriad Genetics reported on Tuesday that its third quarter revenues fell 7 percent year over year primarily due to currency translations and change of estimates in diagnostic test cash collection, and non-recurring milestone payments.

In the evening of October 28, YHLO released its 2022 third quarterly report, the company achieved revenue of CNY 3.129 billion in the first three quarters of 2022, an increase of 265.06% year-on-year

Thermo Fisher Scientific said on Monday that it has reached a definitive agreement to acquire The Binding Site Group, a UK-based specialty diagnostics company, for ￡2.25 billion ($2.60 billion) in cash.

Beckman Coulter Life Sciences announced on Monday that it has inked an application development agreement with Pillar Biosciences for next-generation sequencing solutions.

Gongdong Medical Technology announced that it plans to increase the capital of its wholly owned subsidiary GD Medical with its own funds or self-raised funds of 45 million US dollars to acquire the core assets of Trademark Plastics Inc. ("TPI").